CLXPF News and Press, Canadian Lynx Pete Ltd From 05/11/21

Since selective serotonin reuptake inhibitor antidepressants (“SSRIs”) were introduced in the late ‘80s, little has changed in how different mental health conditions are treated. The co-founder of the Institute for Integrative Therapies (“IIT”) Manoj ...

Company committed to building presence in U.S. and Europe to advance mission of improving mental health care New appointments will strengthen Cybin’s development and clinical operations globally, solidify position within the industry New leaders bring broad experience, deep ins...

Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, announced that CEO Doug Drysdale will be presenting at the upcoming Benzinga Global Small Cap Conference. The conference, slated for Thursday, May 13, 2021, is designed to connect pro...

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Benzinga Glob...

A new study has discovered that individuals under the influence of psilocybin tend to have more original and profound thoughts. However, cognitive tests on creative ability conducted have shown that they score lower in the short term, with findings indicating that psilocybin, which is the ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Psychedelics could be a game-changer for millions struggling with mental health issues. And as a result, psychedelic stocks could be a game-changer for your portfolio. Psilocybin, for example, has been shown to help with ...

Agreement calls for Cybin, Catalent to work together to develop novel therapy for treatment-resistant psychiatric disorders Cybin looking to identify fast-acting, shorter-duration formulations of CYB003 Delivering CYB003 through Catalent ODT could provide significant benefits Cybi...

Last week, a federal health agency begun a speaker series that will be focused on reviewing the science behind psilocybin mushrooms and the therapeutic potential they possess. Experts who aired their views at the inaugural event claimed that federal drug regulations undermined the scientif...

Cybin (NEO: CYBN) (OTCQB: CLXPF) , a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has completed key in-vitro and in-vivo research studies. The company recently announced completion of its 20th pre-clinical study and the progre...

A clinical trial whose results were published last week has found that psilocybin may be used to treat depression. The phase 2 study was the first randomized trial that compared the effectiveness of commonly prescribed antidepressants with therapeutic doses of psilocybin. Its findings we...